Q-omics provides the consensus-scored MIR8058 profile across patient tissues and cancer cell-line models. MIR8058 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR8058 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, MIR8058 RNA expression shows 9,515 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where MIR8058 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8058 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8058 survival associations across molecular data types. MIR8058 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8058 RNA expression–survival associations across cancer types. High MIR8058 expression shows unfavorable associations in MESO, CHOL, ACC and THCA, but favorable associations in BRCA and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR8058 RNA expression.
This table summarizes MIR8058 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8058. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8058 shows lower tumor expression in BRCA, BLCA and COAD and higher tumor expression in HNSC, KIRC and LUSC. The HNSC box plot shows higher MIR8058 RNA expression in tumor versus normal tissue (log2 FC = +0.890, t-test p < 0.001).
This table shows molecular features associated with MIR8058 in patient tissues and cancer cell lines. In patient samples, MIR8058 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
